# A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy

> **NCT05464719** · PHASE2 · RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 30 (estimated)

## Conditions studied

- Large B-cell Lymphoma
- Lymphoma

## Interventions

- **DRUG:** Loncastuximab Tesirine

## Key facts

- **NCT ID:** NCT05464719
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-09-23
- **Primary completion:** 2030-01-30
- **Final completion:** 2030-01-30
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-01-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05464719

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05464719, "A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05464719. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*